Alimera Sciences, Inc., a privately
held biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic
pharmaceuticals, reported that after completing its review of safety
and efficacy data currently available, an independent Data Safety
Monitoring Board (DSMB) has again recommended that the two pivotal Phase 3
clinical trials for the use of Iluvien(TM) in the treatment of diabetic
macular edema (DME) continue under the current protocol, without change. A
DSMB provides an independent evaluation of all trial data to identify
potential safety issues that might warrant modification or early
termination of ongoing clinical studies.
These clinical trials, known collectively as the FAME(TM) Study
(Fluocinolone Acetonide in Diabetic Macular Edema), consist of two double
masked, randomized, multi-center trials that are following 956 patients in
the U.S., Canada, Europe and India for 36 months in support of a planned
global registration filing, with safety and efficacy assessed after 24
months of follow-up. Enrollment for the FAME study was completed in October
2007.
“Alimera is excited about the potential of Iluvien to help the growing
number of people suffering from DME,” said Alimera CEO Dan Myers. “The
DSMB’s recommendation to continue the FAME Study without change keeps the
development for Iluvien on track for regulatory submissions in early 2010.”
Iluvien is an intravitreal insert being developed for the treatment of
DME. DME is a disease of the retina, which affects individuals with
diabetes and can lead to severe vision loss and blindness. Each Iluvien
insert is designed to provide a sustained therapeutic effect, up to 36
months for the low dose and up to 24 months for the high dose. Iluvien is
inserted into the patient’s eye with a 25-gauge needle, which allows for a
self-sealing wound. This insertion is very similar to an intravitreal
injection, a procedure commonly employed by retinal specialists.
Currently, nearly 24 million people, or 8 percent of the population, in
the U.S. have diabetes. Over time, all diabetics are at risk of developing
some form of diabetic retinopathy, an ophthalmic condition of diabetes. In
the U.S., diabetic retinopathy causes approximately 12,000 to 24,000 new
cases of blindness each year, making diabetes the leading cause of new
cases of blindness in adults aged 20 to 74. Based on published data,
Alimera estimates that there are as many as 300,000 new cases of DME each
year and 1 million people have DME. There are no ophthalmic drug therapies
currently approved by the U.S. Food and Drug Administration for the
treatments of DME.
About Alimera Sciences, Inc.
Alimera Sciences is a biopharmaceutical company that specializes in the
research, development and commercialization of prescription ophthalmic
pharmaceuticals. Presently the company is focused on diseases affecting the
back of the eye, or retina. Its most advanced product candidate is
Iluvien(TM), which is being developed for the treatment of diabetic macular
edema, or DME. DME is a disease of the retina, which affects individuals
with diabetes and can lead to severe vision loss and blindness. Under one
protocol, enrollment was completed in October 2007 in two Phase 3 pivotal
trials for the use of Iluvien in the treatment of DME conducted across the
U.S., Canada, Europe and India, with a combined total enrollment of 956
patients.
Alimera also has entered into an exclusive worldwide agreement with
Emory University to explore oxidative stress management — specifically the
reduction of reactive oxygen species (ROS) — as a treatment strategy for
ophthalmic diseases. Under this agreement, Alimera has acquired options to
exclusive, worldwide licenses for two classes of nicotinamide adenine
dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which
Alimera is studying as potential treatments for conditions such as the dry
form of age-related macular degeneration (AMD), particularly the late stage
of this condition known as geographic atrophy. Alimera has exercised its
option to acquire a license with respect to one of these classes of NADPH
oxidase inhibitors.
Alimera Sciences
www.alimerasciences